Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope?

被引：6

作者：

Diefenbach, Catherine ^{[1
]}

Advani, Ranjana ^{[2
]}

机构：

[1] NYU, Sch Med, Ctr Canc, Dept Med, New York, NY 10016 USA

[2] Stanford Univ, Med Ctr, Stanford Canc Ctr, Stanford, CA 94305 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2014年 / 28卷 / 01期

关键词：

Hodgkin lymphoma; Relapsed disease; Targeted therapies; Brentuximab vedotin; STEM-CELL TRANSPLANTATION; REED-STERNBERG CELLS; EPSTEIN-BARR-VIRUS; TUMOR-ASSOCIATED MACROPHAGES; HIGH-DOSE THERAPY; BRENTUXIMAB VEDOTIN; PHASE-I; PROGNOSTIC-FACTORS; ALLOGENEIC TRANSPLANTATION; MOLECULAR PATHOGENESIS;

D O I：

10.1016/j.hoc.2013.10.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical need. Recent advances in unraveling the biology of HL have yielded a plethora of novel targeted therapies. This review provides an overview of the data behind the hype generated by these advances and addresses the question of whether or not clinically these targeted therapies offer hope for patients with HL.

引用

页码：105 / +

页数：19

共 50 条

[1] Targeted therapy in the management of lung cancer: is there more hype than hope?
Frances A. Shepherd
[J]. Targeted Oncology, 2008, 3 : 131 - 133
[2] Targeted therapy in the management of lung cancer: is there more hype than hope?
Shepherd, Frances A.
[J]. TARGETED ONCOLOGY, 2008, 3 (03) : 131 - 133
[3] Targeted Therapy in Relapsed Classical Hodgkin Lymphoma
Dinner, Shira
Advani, Ranjana
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (08): : 968 - 976
[4] Genetic lesions and targeted therapy in Hodgkin lymphoma
Li, Zhe
Mu, Wei
Xiao, Min
[J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2023, 14
[5] Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy
Grover, Natalie S.
Park, Steven I.
[J]. PHARMACEUTICALS, 2015, 8 (03) : 607 - 636
[6] Does hope match the hype for targeted drugs?
Brown, H
[J]. LANCET ONCOLOGY, 2003, 4 (08): : 452 - 452
[7] Metabolic Tumor Volume in Lymphoma: Hype or Hope?
Schoder, Heiko
Moskowitz, Craig
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (30) : 3591 - +
[8] Problems and promises of targeted therapy for Hodgkin's lymphoma
Daniel Re
Roman K Thomas
Thomas Zander
Volker Diehl
[J]. Nature Clinical Practice Oncology, 2005, 2 : 2 - 3
[9] Problems and promises of targeted therapy for Hodgkin's lymphoma
Re, D
Thomas, RK
Zander, T
Diehl, V
[J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (01): : 2 - 3
[10] The hope and hype of stem cell therapy
Oh, Il-Hoan
[J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2013, 56 (10): : 848 - 851

← 1 2 3 4 5 →